Brain-Computer Interface

At a State Council Information Office press conference on the 15th Five-Year Plan, the Ministry of Industry and Information Technology said it will stay application-driven, deepen the implementation of AI plus manufacturing, support research and development of key technologies such as high-end training chips and multimodal algorithms, tackle frontier technologies including brain-inspired intelligence and world models, advance the iteration of intelligent terminals such as humanoid robots and brain-computer interfaces, and distill high-value scenarios by industry while rolling out a batch of lightweight, low-cost, easy-to-deploy industry solutions. Multiple products under China Southern Fund are positioned in the artificial intelligence industry, including China Southern Digital Economy Mixed Fund, China Southern Technology Pilot Mixed Fund, China Southern Yihe Flexible Allocation Mixed Fund, China Southern Emerging Leaders Flexible Allocation Mixed Fund, and China Southern China Dream Flexible Allocation Mixed Fund.

The Ministry of Industry and Information Technology released on August 24 a draft for comments of the National Brain-Computer Interface Industry Standards System Construction Guidelines 2026 Edition, proposing to formulate or revise more than 40 standards in the brain-computer interface field by 2028 and to promote standards publicity and implementation among over 100 enterprises. In early trading today, consumer sector indices such as daily chemicals, tourism, and hotels and catering led gains, with the daily chemicals industry rising the most. Proya, Betaini, and SYoung Group all gained more than 5 percent, while Qingdao Kingking shot up and sealed the daily limit within two minutes, becoming the only limit-up stock in the daily chemicals sector. Brain-computer interface concept stocks have fallen an average of 15.74 percent this year, but since August the average daily turnover of 10 concept stocks has increased month on month. Beijing Beilu Pharmaceutical had an average daily turnover of 317 million yuan, up 71.83 percent month on month, ranking first. According to statistics from Securities Times Data Treasure, there are currently more than 30 A-share concept stocks involved in the brain-computer interface industry chain, with companies such as Medlander, Vishee, Meihao Medical, Apon Medical, and ZKTeco all having layouts.

Brain-computer interface technology is accelerating its move from the laboratory into clinical and consumer markets. The global market is expected to exceed 360 billion yuan by 2035, with China likely to account for more than 30 percent of that share. Neuralink has announced completion of the world's first brain-computer interface surgery implanted through the dura mater, while China's first subdural implantable brain-computer interface system has also begun national Class III medical device registration clinical trials. Companies listed in both A-share and Hong Kong markets, such as Wision Medical, Sanbo Brain Hospital, and MicroPort NeuroTech, have already achieved commercial revenue through non-invasive rehabilitation, clinical data assets, and implantable products. On the policy front, brain-computer interfaces have been included in the future industries section of the 15th Five-Year Plan. Beijing, Shanghai, and Guangdong have introduced targeted support policies, and an industry standardization technical committee has also been established. Institutions expect 2027 to become the first year of commercial explosion for brain-computer interfaces.

The medical device sector rebounded in afternoon trading, with Biolight hitting the 20% daily limit up. Earlier, Chaoyan Medical rose by the daily limit, Aohua Endoscopy gained over 10%, and Apon Medical, Rendu Biotechnology, Haitex, Nanwei Medical, and Lude Medical also followed the upward trend. The General Office of the Zhejiang Provincial People's Government issued several measures this morning to promote industry-academia-research collaboration in brain-computer interfaces, aiming for future industry revenue from brain-computer interfaces to exceed 5 billion yuan by 2027, and to establish a globally competitive hub for brain-computer interface technology and industry innovation by 2030.

The Ninth Central China Rehabilitation Forum and the Eleventh Rehabilitation Equipment Expo were held in Anyang, Henan. The Brain-Computer Interface Rehabilitation Technology Innovation Consortium, led by Xiangyu Medical, expanded again, with seven medical institutions including the First Affiliated Hospital of Nanchang University officially joining. Xiangyu Medical also established a joint brain-computer interface laboratory with the School of Rehabilitation at Wenzhou Medical University, and signed clinical strategic cooperation agreements with institutions such as Tongji Hospital affiliated with Tongji Medical College of Huazhong University of Science and Technology. On the international front, Xiangyu Medical signed a strategic cooperation agreement with the team of international expert Professor Guttenbrunner, and two international platforms—the Rehabilitation International-China Cooperation Center and the International Shockwave Training Base—were unveiled. The expo showcased over a thousand smart rehabilitation products, with the brain-computer interface smart care ward taking center stage. This solution uses non-invasive brain-computer interfaces as its core, enabling patients to control ward facilities through thought. Xiangyu Medical has built a brain-computer rehabilitation product matrix covering scenarios such as movement, cognition, speech, and swallowing. Intelligent devices like the infrared light moxibustion robot and lower-limb exoskeleton rehabilitation robot were also on display. At the policy level, brain-computer interfaces have been included in the government work report's list of future industries to cultivate and in the forward-looking layout of key tracks in the 15th Five-Year Plan outline. In 2024, China's brain-computer interface market reached 3.2 billion yuan, up 18.81 percent year-on-year, and is expected to grow to 4.6 billion yuan by 2026. Xiangyu Medical's 2025 annual report shows that R&D spending accounted for as much as 24.65 percent of operating revenue, underpinning its technology reserves.

The Sci-Tech Innovation Board Medical ETF Huaxia, ticker 588130, saw its latest shares reach 456 million, a one-year high. As of 2:07 PM on July 29, 2026, the ETF rose 0.91 percent, with the latest price at 1 yuan, intraday turnover rate of 13.39 percent, and trading volume of 60.8075 million yuan. The Shanghai Sci-Tech Innovation Board Biomedical Index it tracks surged 1.19 percent, with constituent stock Haoyuan Chemexpress rising 9.32 percent and Baili Tianheng rising 4.87 percent. In related news, the 2026 government work report for the first time explicitly designated biomedicine as an emerging pillar industry. The 15th Five-Year Plan listed brain-computer interfaces as a frontier core industry. The leap in top-level policy positioning, combined with China's innovative drug license-out deals hitting a record high and the first prescription for the implantable brain-computer interface NEO, marks the track's transition from the laboratory to clinical application.

Mehow Medical recently added a core invention patent, with patent publication number CN122140259A, titled "Self-Generating Neural Electrode and Manufacturing Method Thereof," officially disclosed. The patent addresses the long-term implantation pain points of invasive brain-computer interfaces, innovatively achieving in-situ self-generating repair of electrodes, alleviating the problems of impedance rise and neural signal attenuation after implantation, and effectively enhancing the long-term working stability and biocompatibility of neural electrodes. Leveraging its mature precision manufacturing capabilities for implantable medical devices, Mehow Medical is deeply engaged in the invasive neural electrode track, reusing precision processing and biocompatible encapsulation technologies from cochlear implants, and laying out core implant components for brain-computer interfaces. It provides process development and mass production support for leading domestic BCI enterprises, with related electrode components already in small-batch supply. As the brain-computer interface industry accelerates toward clinical implementation, long-lasting implant electrodes, as key hardware in the industry chain, are expected to see sustained demand growth.

The brain-computer interface concept continued its strong momentum in early trading on July 28, with Innovative Medical hitting a 4-day 3-board streak, and Hainan Haiyao, Yanshan Technology, and Thalys Medical hitting the daily limit up. The core catalyst for this rally came from an overseas commercialization milestone: US startup Science Corp.'s retinal chip PRIMA has received EU CE certification, becoming the world's first brain-computer interface device to obtain this certification, and has been approved for sale in 30 European countries. On the domestic front, a Chinese research team unveiled a new EEG signal acquisition device, achieving the world's first cross-regional synchronous EEG signal collection from over a thousand people. The implantable brain-computer interface hand motor function compensation system NEO issued its first prescription in Shanghai and completed the world's first implant surgery. Capital market enthusiasm is high, with total financing in China's brain-computer interface sector exceeding 4.4 billion yuan from January to May 2026, more than doubling the full-year total of last year. A research report from Zheshang Securities pointed out that the market size for brain-computer interface demand in China's serious medical field alone could reach 20 to 60 billion yuan, while the global market is projected to grow from 2.41 billion dollars in 2025 to 12.11 billion dollars in 2035, at a compound annual growth rate of 15.8 percent. Southwest Securities judged that 2026 will be the first year of mass production for brain-computer interfaces, with the industry at the tail end of the introduction phase and on the eve of an explosion.

Major breakthroughs in the brain-computer interface field both domestically and internationally have lifted the STAR Market Healthcare ETF Huaxia by 1.90 percent, with the latest price at 1.02 yuan. US startup Science Corp. has received approval to sell a retinal chip in the European Union that helps patients with geographic atrophy restore partial vision, marking the first time a US brain-computer interface company has brought such a device to the patient market at scale. Meanwhile, a domestic research team has unveiled a new electroencephalogram signal acquisition device, achieving the world's first simultaneous EEG signal collection from over a thousand people across different regions. On the capital flow front, the STAR Market Healthcare ETF Huaxia has seen net inflows for four consecutive days, attracting a total of 94.75 million yuan, with the highest single-day net inflow reaching 65.11 million yuan. Huafu Securities noted that it remains firmly bullish on the sustainability of the pharmaceutical sector rally, recommending a focus on innovative drugs and the industry chain, while also paying attention to the incremental opportunities from medical device exports, particularly hot areas such as surgical robots and brain-computer interfaces.

On July 27, brain–computer interface concept stocks surged across the board. Aipeng Medical hit the 20 percent daily limit up, Chengdu Sino Microelectronics rose 13.48 percent, Breo Technology gained 10.45 percent, Sanbo Brain Hospital advanced 10.44 percent, and Saili Medical, Chuangxin Medical, and Nanjing Panda all touched the daily limit up. Among them, Chuangxin Medical achieved three boards in two days. On the news front, US brain–computer interface startup Science Corp has received approval to sell a retinal chip in the European Union that can help restore partial vision in patients with geographic atrophy. This marks the first time a US brain–computer interface company has brought a related device to the patient market at scale. The company was valued at 1.5 billion dollars in March, making it the second most valuable brain–computer interface firm in the United States. In addition, Shanghai recently introduced measures to promote the listing of brain–computer interface and other emerging industry companies on the STAR Market, and a Chinese research team has unveiled a new type of EEG acquisition device that, for the first time globally, enables synchronous EEG signal collection from over a thousand people across different locations.

Domestic brain-computer interface technology has achieved a major breakthrough, realizing for the first time the synchronous collection of brainwave signals from over a thousand people across different regions, marking a key step toward neural large model training and general brain-computer interface technology research and development. Driven by this news, brain-computer interface concepts were active during the session. The Sci-Tech Innovation Pharmaceutical ETF Penghua saw active trading. As of 9:49 a.m. on July 24, 2026, the ETF's latest quote was 1.05 yuan, with an intraday turnover rate of 2.24 percent and a trading volume of 7.47 million yuan. As of July 23, the ETF's average daily trading volume over the past month was 23.76 million yuan. The Sci-Tech Innovation Pharmaceutical ETF Penghua closely tracks the Shanghai Stock Exchange Science and Technology Innovation Board Biomedical Index. The top ten weighted stocks of this index include United Imaging Healthcare, Allist Pharmaceuticals, and BeiGene, accounting for a total of 51.84 percent. A research report from China Securities recommends paying attention to undervalued and high-growth stocks in the medical device sector, and points out that new technology directions such as surgical robots and brain-computer interfaces are expected to continue catalyzing sector enthusiasm.

Science Corp, a US neurotechnology startup, will begin selling its Prima retinal implant chip in Europe after receiving CE marking, which partially restores vision for patients with geographic atrophy due to age-related macular degeneration without requiring additional country-by-country approvals. It is the first implantable device from the company, which also develops brain implants, to become widely available to patients. The Prima device is a chip placed behind the eye that works with special glasses. According to research published in the New England Journal of Medicine last year, it improved vision in 26 out of 32 patients. The company expects to implant the device in its first commercial patient in August, likely in Germany, and aims to implant dozens of patients this year and around 200 next year. Science Corp has raised 489 million dollars and is valued at 1.5 billion dollars, making it the second most valuable US brain implant technology company after Elon Musk's Neuralink.

In early trading on July 16, Harbin Pharmaceutical hit its fifth consecutive daily limit, making it the stock with the longest winning streak among those still on a streak that day. The innovative drug theme remained strong, with Wanbang Pharmaceutical and Puruis rising over 10 percent. The on-device AI concept heated up, as Green Precision sealed a 20 percent daily limit, and Daoming Optics and Furong Technology also hit their daily limits. On the news front, seven on-device generative AI services completed regulatory filings, and the 2026 World Artificial Intelligence Conference is set to take place in Shanghai. The brain engineering sector saw a sudden surge during the session, with Chuangxin Medical hitting its daily limit in a straight line, and Saili Medical and Aipeng Medical following higher. The world's first implantable brain-computer interface system, NEO, saw its first prescription issued in Shanghai after receiving market approval. Total market turnover exceeded 1.4 trillion yuan, shrinking by 236.7 billion yuan compared with the same period last session, with over 3,200 stocks advancing.

The commercialization of brain-computer interface technology has achieved a key milestone, with the first prescription for an implantable brain-computer interface system issued in Shanghai, triggering a collective surge in concept stocks. The Shanghai Municipal Science and Technology Commission announced on July 15 that the first prescription for the implantable brain-computer interface hand motor function compensation system, NEO, developed by Neuracle Technology Shanghai, was issued in Shanghai on July 13, following its market approval. On the same day, the world's first implantation surgery for the product was completed at Huashan Hospital affiliated with Fudan University. The NEO system is the world's first approved invasive brain-computer interface Class III medical device, taking only four months from obtaining the world's first regulatory approval to issuing the first clinical prescription. A breakthrough has also been achieved on the payment side. The city-customized commercial supplementary medical insurance, Shanghai Huhui Bao 2026 Edition, has for the first time included coverage for brain-computer interface surgical consumables, with a reimbursement rate of 30 percent and a maximum coverage limit of 150,000 yuan, making it the first urban inclusive insurance product nationwide to cover brain-computer interfaces. Capital market enthusiasm is high. From January to May 2026, total financing in China's brain-computer interface sector exceeded 4.4 billion yuan, more than doubling the total for the entire previous year. Neuracle's IPO application has been accepted, and BrainCo is also expected to go public.

NeuroTiger Technology's self-developed fully implantable, fully wireless, fully functional brain-computer interface system has officially launched a GCP registration clinical trial at Huashan Hospital affiliated with Fudan University. This is the first subdural cortical surface implantable brain-computer interface product in China to enter the national Class III medical device registration clinical stage. The Sci-Tech Innovation Board Medical and Healthcare ETF Huaxia has seen net inflows for eight consecutive days, attracting a total of 99.82 million yuan. As of 2:28 p.m. on July 8, constituents of the Shanghai Stock Exchange STAR Board Biomedical Index were mixed, with Aibo Medical leading gains at 4.02 percent. Huaxin Securities noted that policies are tilting toward incremental areas such as surgical robots and brain-computer interfaces, making expansion and innovation an important path for medical device companies.

The Ministry of Civil Affairs reported that by the end of 2025, the number of elderly care institutions and facilities in China had reached 396,000, with nursing beds accounting for 67.5 percent of all beds in these institutions. County-level public elderly care institutions have achieved near-universal coverage, and about 30 percent now function as comprehensive county-level elderly care service management platforms. Over 60 percent of townships and subdistricts have established regional elderly care service centers, marking initial progress in building a three-tier elderly care service network across the country. The People's Bank of China Monetary Policy Committee stressed at its second-quarter regular meeting for 2026 that it will continue to implement a moderately accommodative monetary policy, strengthen counter-cyclical and cross-cyclical adjustments, and maintain ample liquidity. NeuroHarbor's self-developed implantable brain-computer interface system has officially launched a GCP registration clinical trial at Huashan Hospital affiliated with Fudan University. This is the first subdural cortical surface implantable brain-computer interface product in China to enter the national Class III medical device registration clinical stage. Tianhao Energy plans to acquire 100 percent equity of Tianhao New Energy Co., Ltd. through a combination of share issuance and cash payment. Trading of the company's shares and convertible bonds will resume on July 9, 2026. On July 8, net outflow of main funds from the Shanghai and Shenzhen stock markets reached 69.823 billion yuan, with the IT services, computer equipment, and communication equipment sectors seeing the largest net inflows of main funds.

The Sci-Tech Innovation Board Healthcare ETF Huaxia has reached a latest scale of 176 million yuan, a nearly one-year high. As of the close on July 6, 2026, the ETF was quoted at 1.09 yuan, with intraday turnover of 38.61 percent and trading volume of 68.44 million yuan. A relevant official from the Ministry of Science and Technology stated that future industries will be forward-laid out, with a focus on promoting biomanufacturing and brain-computer interfaces as new economic growth points. Aijian Securities noted that a good opportunity for medium- to long-term positioning in the pharmaceutical sector has arrived, and it continues to favor investment opportunities such as innovative drug going overseas and brain-computer interfaces.

China's first ultrasound brain-computer interface company Gestalt Tech has completed a 420 million yuan angel+ round of financing. This round was led by Huaying Capital, with follow-on investments from C Capital, Sequoia China, Lens Technology, China Electronics Health Fund, Sinovation Ventures, Lingang Sci-Tech Innovation Investment, Fudan Furong Capital, and Guotai Venture Capital, among other leading domestic and international investment institutions. Existing shareholders including Daotong Investment, Yunshi Capital, Qingsong Capital, and Gobi Partners continued to oversubscribe. China Renaissance acted as the exclusive financial advisor. At the same time, Gestalt Tech's Shanghai headquarters in the Brain Intelligence Park in Minhang District was officially inaugurated. As of 14:18 on July 3, 2026, the Shanghai Stock Exchange STAR Biomedical Index rose strongly by 2.69 percent. Among constituent stocks, MGI Tech rose 14.97 percent, Dizal Pharmaceutical rose 10.77 percent, and Olym Biotech rose 8.82 percent, with stocks like Youcare Pharmaceutical and Yundong Biotech also rising. The STAR Medical ETF Huaxia rose 2.17 percent, heading for a fifth consecutive gain, with the latest price at 1.08 yuan. CICC believes that innovative fields represented by AI plus healthcare and brain-computer interfaces are experiencing rapid development, with systems from supporting policies to capital support gradually improving, and such directions may present structural investment opportunities.

Butterfly Network's embedded partner Aleph Neuro has unveiled what it describes as the highest-resolution 3D images of the human brain captured non-invasively using Butterfly's Ultrasound-on-Chip platform. The announcement marks another validation of Butterfly Network's Embedded licensing and co-development business, extending the reach of its technology beyond traditional point-of-care imaging into emerging applications such as brain-computer interfaces. While the development is still at an early stage and is unlikely to have an immediate financial impact, it reinforces Butterfly Network's long-term growth prospects by showcasing the versatility of its platform and its ability to unlock future licensing opportunities. Aleph Neuro's approach combines Butterfly's Ultrasound-on-Chip technology with advanced imaging techniques to produce MRI-like brain images without invasive procedures or large, expensive MRI systems. The milestone comes shortly after another Butterfly Embedded partner unveiled a full-body ultrasound CT scanner, underscoring the versatility of the company's proprietary semiconductor-based ultrasound technology across diverse applications.

CeriBell reported a study showing that higher AI-detected seizure burden is linked to increased odds of disability at discharge. The study, published in Critical Care Medicine, analyzed 359 adult patients across three academic centers and found that patients with a peak seizure burden of at least 90% were 3.4 times more likely to experience death or severe disability compared to those with no seizure burden. Each additional hour of AI-detected seizure activity nearly doubled the odds of severe disability or death, with an adjusted odds ratio of 1.98. Lead author Josef Parvizi said the algorithm detects clinically relevant biomarkers with prognosis, underlining potential for earlier intervention, while CEO Jane Chao noted that continuous monitoring allows live assessment and more informed clinical decisions.

The global brain implants market is projected to grow from USD 7.10 billion in 2025 to USD 18.39 billion by 2035, expanding at a compound annual growth rate of 9.99 percent, according to a new report by SNS Insider. North America held the largest share in 2025, with the U.S. market alone valued at approximately USD 3.16 billion and expected to reach USD 8.17 billion by 2035. The deep brain stimulators segment accounted for about 37.6 percent of total revenue in 2025, while Parkinson's disease represented the largest application segment at roughly 34.3 percent. The Asia-Pacific region is forecast to be the fastest-growing market, driven by rising neurological disease prevalence and expanding neurosurgical infrastructure.

Precision Neuroscience has won a 2026 Webby Award and earned a spot on Fast Company's World Changing Ideas list for the second consecutive year. The Webby Awards recognized the company's Layer 7 cortical interface for its potential to restore communication for people living with paralysis. Fast Company's list honors bold efforts tackling pressing issues, and Precision's flagship device is a high-resolution, minimally invasive, non-penetrating surface electrode array that can be safely removed and upgraded. The device uses 1,024 thin-film electrodes and AI software to decode neural data in real time, enabling thought-based control of digital interfaces. In April 2025, Precision received FDA 510(k) clearance for the Layer 7 device for up to 30 days of use, and it has been implanted in more than 90 patients across multiple health systems.